Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

Recruiting

• Conditions: Thyroid Neoplasms
• Interventions: Drug: Anlotinib Hydrochloride Capsule

• Registration Number: NCT05994365
• Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Brief Summary

The study aims to observe and investigate the efficacy and safety of Anlotinib capsules in patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma in the real world, and to summarize the treatment experience in a broad population.

Detailed Description

Not available

Study Timeline

• Status Verified: 2023-08
• Study Start: 2023-08
• Study First Submitted: 2023-08-09
• Study First Submitted QC: 2023-08-09
• Last Update Submitted: 2023-08-09
• Study First Posted: 2023-08-16
• Last Update Posted: 2023-08-16
• Primary Completion: 2027-08
• Study Completion: 2028-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 380

Inclusion Criteria

• Patients voluntarily participate in this study, sign the informed consent form and had good compliance;

• Aged 18 ~ 70 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0~1; more than 6 months of expected survival ;

• Histopathologically confirmed locally advanced or metastatic differentiated thyroid cancer, radiographically documented disease progression within 18 months of absence of radioactive iodine (RAI) therapy;

• Meet any of the following:

  1. Lesions were not iodine-avid: no RAI uptake was confirmed after RAI scan in the presence of a low-iodine diet, adequate thyroid stimulating hormone (TSH) elevation (≥ 30 mIU/L). The definition of no iodine uptake:

     1. no iodine uptake initially;
     2. exist of iodine uptake initially while lost subsequently;
     3. partially uptake;
     4. progression disease despite iodine uptake.

  2. The cumulative dose of RAI was ≥ 600 mCi or 22 GBq, with an interval of at least 3 months.

  3. Radiographically documented disease progression within 18 months of RAI therapy despite the presence of iodine-131 affinity at the time of RAI therapy;

• At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1.

• Major organ functions meet the following criteria within 7 days prior to treatment:

  1. Blood routine test criteria (14 days without blood transfusion):

     1. Hemoglobin (HB) ≥ 85 g/L;
     2. Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L;
     3. Platelet (PLT) ≥ 80 × 10^9/L

  2. Biochemical tests need to meet the following criteria:

     1. Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN);
     2. Alanine aminotransferase (ALT) and aspartate aminotransferase AST ≤ 2 .5×ULN, ALT and AS if liver metastases T ≤ 5 ×ULN;
     3. Serum creatinine (Cr) ≤ 1 .5 ×ULN or creatinine clearance (CCr) ≥ 60 Ml/min;

• Females of childbearing potential should agree to use contraceptive measures (such as intrauterine device, contraceptives or condoms) during the study and within 6 months after the end of the study; have a negative serum or urine pregnancy test within 7 days before study enrollment and must be non-lactating patients; and males should agree to use contraceptive measures during the study and within 6 months after the end of the study period.

Exclusion Criteria

• Comorbidities and medical history:

  1. A history of or concurrent with other malignancies within the past 3 years. Patients were eligible if they had disease-free survival (DFS) for 5 consecutive years in other malignancies treated by single surgery; Cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)];

  2. Major surgical treatment, open biopsy, or significant traumatic injury within 28 days before the start of study treatment;

  3. Subjects with any severe and/or uncontrolled illness, including:

     1. Patients with ≥ grade 2 myocardial ischemia or myocardial infarction, arrhythmia (including Corrected QT Interval (QTc)≥450ms(male), QTc≥ 470ms(female)) and ≥ grade 2 congestive heart failure (NYHA classification);
     2. Severe active or uncontrolled infection (≥ grade 2 infection according to Common Terminology Criteria for Adverse Events (CTCAE) );
     3. Renal failure requiring hemodialysis or peritoneal dialysis;

• Patients with concomitant diseases that seriously endanger the safety of patients or affect the completion of the study, or patients who are considered to be unsuitable for enrollment for other reasons according to the judgment of the investigators.

• patients with previous treatment with anlotinib hydrochloride capsules or similar vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) small molecule drugs, such as vandetanib, Cabozantinib, lenvatinib, sunitinib, or sorafenib, etc.;

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Anlotinib group	Anlotinib Hydrochloride Capsule	Anlotinib hydrochloride capsules: 12 mg once daily for 2 weeks, followed by a discontinuation of 1 week (21 days as a cycle)

Primary Outcome Measures

Name	Time	Method
Overall Response Rate (ORR)	Baseline up to 3 years.	The proportion of subjects who achieves a best overall response of complete response (CR) or partial response (PR).
Progression-free Survival (PFS)	Baseline up to 3 years.	From the first dose to the date of objective disease progression or death, whichever occurs first.

Secondary Outcome Measures

Name	Time	Method
Duration of Response (DOR)	Baseline up to 3 years.	From the date that CR or PR are first occurred to the date of objective disease progression or death, whichever occurs first.
Overall Survival (OS)	Baseline up to 3 years.	From randomization to the time of death from any cause.
Disease-control Rate (DCR)	Baseline up to 3 years.	The proportion of subjects response of CR, PR, or stable disease (SD), subjects achieving SD will be included in the DCR if they maintain SD for ≥4 weeks.
Adverse event rate	Baseline up to 3 years.	The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).

Trial Locations

Locations (3)

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; 🇨🇳 Beijing, Beijing, China

Tianjin People's Hospital; 🇨🇳 Tianjin, Tianjin, China

Tianjin Cancer Hospital; 🇨🇳 Tianjin, Tianjin, China